Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 17/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059384 | 0.91 | MCHR1 (0.70) | MCHR1KCNH2MAPK14 | |
| SCHEMBL17979380 | 0.87 | MCHR1 (0.66) | MCHR1KCNH2 | |
| SCHEMBL1753482 | 0.87 | MCHR1 (0.66) | MCHR1KCNH2MAPK14 | |
| SCHEMBL2571449 | 0.86 | MCHR1 (0.66) | MCHR1KCNH2 | |
| SCHEMBL4379409 | 0.84 | MCHR1 (0.65) | MCHR1KCNH2 | |
| SCHEMBL1549894 | 0.83 | MCHR1 (0.65) | MCHR1KCNH2MAPK14 | |
| SCHEMBL1753726 | 0.82 | MCHR1 (0.57) | MCHR1KCNH2MAPK14 | |
| SCHEMBL2890948 | 0.81 | MCHR1 (1.00) | MCHR1KCNH2 | |
| SCHEMBL14138242 | 0.81 | MCHR1 (0.57) | MCHR1KCNH2 | |
| SCHEMBL4729570 | 0.80 | MCHR1 (0.62) | MCHR1KCNH2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732456-B2 | Pyridone derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-08 | — | — | US | disclosed |
| US-20070208046-A1 | Pyridone derivative | MSD K.K. (JP) | 2007-09-06 | — | — | US | disclosed |
| CN-1930126-A | Pyridone Derivatives | BANYU PHARMA CO LTD (JP) | 2007-03-14 | — | — | CN | disclosed |
| EP-1741703-A1 | PYRIDONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208046-A1 | Pyridone derivative | CHRM1, XDH, MTR | MCHR1 535/4885KCNH2 1619/4885MAPK14 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.